TY - JOUR T1 - Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 4668 AU - Makoto Hoshino Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/4668.abstract N2 - Background:Combining LAMA (long-acting muscarinic antagonist) with LABA (long-acting ß2 agonist) has been shown to be pharmacologically useful in patients with COPD.Aims and objectives:The aim of the present study was to evaluate the effectiveness of the dual bronchodilators on airway dimensions in COPD.Methods:Patients (n = 54) were randomly assigned receive to tiotropium (18 µg once daily), indacaterol (150 µg once daily), or tiotropium plus indacaterol for 16 weeks. Quantitative computed tomography (CT) analysis, pulmonary function and health status SGRQ (St. George's Respiratory Questionnaire) were performed.Results:Compared with tiotropium or indacaterol alone, combination therapy had a significant decrease in percentage wall area (WA%) and wall thickness (T) corrected for body surface area BSA (T/√BSA), and a increase in luminal area (Ai/BSA). Concurrent treatment was superior to monotherapy in physiological indices including forced vital capacity, FEV1 and inspiratory capacity. The changes in WA% and Ai/BSA were significantly correlated with changes in FEV1 (r = -0.44, p < 0.01 and r = 0.37, p < 0.01).There were more significant improvements in SGRQ scores after treatment with combining therapy than either treatment alone.Conclusions:Concurrent therapy of tiotropium and indacaterol is effective for COPD patients to promote reducing airway wall thickness, bronchodilation and improvement of lung function compared with a single inhaler. ER -